Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen discovers molecule capable of nerve repair
The results suggest a role for LINGO-1 in central nervous system (CNS) repair which could lead to potential pathways for treating multiple sclerosis (MS) and other demyelinating diseases.
The results suggest a role for LINGO-1 in central nervous system (CNS) repair which could lead to potential pathways for treating multiple sclerosis (MS) and other demyelinating diseases.
Results from two new investigational phase III clinical trials showed that oral Hycamtin (topotecan hydrochloride) was clinically active in both small cell lung cancer (SCLC) and non-small cell
The study results form part of an ongoing dual-clinical trial program, named GINEST, evaluating the effectiveness of Gemzar in combination with other leading chemotherapy agents in the treatment
Trials include those conducted in children with solid tumors and in adults with advanced hormone-refractory prostate cancer, advanced gastrointestinal (GI) cancer and small cell lung cancer (SCLC). The
The preliminary data show patients with recurrent glioblastoma multiforme, a form of primary brain cancer, experienced a significant tumor response rate with minimal side effects when treated with
The results demonstrate that Albuferon (albumin-interferon alpha) exhibits more antiviral activity at clinically achieved serum levels than standard interferon alpha or the modified interferons, Roche’s Pegasys (peginterferon alfa-2a)
Omeprazole belongs to a class of proton-pump inhibitors used in the treatment of acid-related gastrointestinal disorders. The product is marketed by Astra Zeneca in Europe under the trade
Lunesta is the first and only sleep aid approved by the FDA for long-term use. Results from two analyses designed to assess potential pharmacoeconomic benefits associated with the
The data indicate a favorable tolerability profile, with evidence of anti-tumor activity in patients with advanced disease. In the phase I trial 52 patients with advanced solid tumors
The collaboration is designed to combine Lexicon’s target discovery and biotherapeutics capabilities with Organon’s clinical development, biologics manufacturing and commercialization franchise to accelerate the development of novel therapeutic